BACKGROUND: Post-treatment control of viraemia after discontinuation of antiretroviral therapy begun during primary HIV-1 infection is considered a potential path toward a sustained remission of infection. METHODS: Subjects enrolled in an observational primary infection cohort who received at least 11 months of highly active antiretroviral therapy beginning within the first 12 weeks of HIV-1 infection and who subsequently discontinued therapy were evaluated for post-treatment control. RESULTS: Within a cohort of 389 subjects with primary HIV-1 infection enrolled over 22 years, only 22 met criteria for evaluation of post-treatment control. Among these subjects, 21 (95%) had loss of viral control (HIV-1 RNA>500 copies/ml) within 18 months after treatment discontinuation, and only 1 (4.5%, 95% CI 0.32, 18.9) controlled viral load to levels <500 copies/ml for at least 24 months. The median time to virological failure was 2.17 (IQR 1.18-3.39) months. CONCLUSIONS: Our data suggest a low likelihood of post-treatment control even when highly active antiretroviral therapy is started within 12 weeks of HIV-1 infection.
BACKGROUND:Post-treatment control of viraemia after discontinuation of antiretroviral therapy begun during primary HIV-1 infection is considered a potential path toward a sustained remission of infection. METHODS: Subjects enrolled in an observational primary infection cohort who received at least 11 months of highly active antiretroviral therapy beginning within the first 12 weeks of HIV-1 infection and who subsequently discontinued therapy were evaluated for post-treatment control. RESULTS: Within a cohort of 389 subjects with primary HIV-1 infection enrolled over 22 years, only 22 met criteria for evaluation of post-treatment control. Among these subjects, 21 (95%) had loss of viral control (HIV-1 RNA>500 copies/ml) within 18 months after treatment discontinuation, and only 1 (4.5%, 95% CI 0.32, 18.9) controlled viral load to levels <500 copies/ml for at least 24 months. The median time to virological failure was 2.17 (IQR 1.18-3.39) months. CONCLUSIONS: Our data suggest a low likelihood of post-treatment control even when highly active antiretroviral therapy is started within 12 weeks of HIV-1 infection.
Authors: R T Davey; N Bhat; C Yoder; T W Chun; J A Metcalf; R Dewar; V Natarajan; R A Lempicki; J W Adelsberger; K D Miller; J A Kovacs; M A Polis; R E Walker; J Falloon; H Masur; D Gee; M Baseler; D S Dimitrov; A S Fauci; H C Lane Journal: Proc Natl Acad Sci U S A Date: 1999-12-21 Impact factor: 11.205
Authors: N Ngo-Giang-Huong; C Deveau; I Da Silva; I Pellegrin; A Venet; M Harzic; M Sinet; J F Delfraissy; L Meyer; C Goujard; C Rouzioux Journal: AIDS Date: 2001-04-13 Impact factor: 4.177
Authors: Eric S Rosenberg; Barney S Graham; Ellen S Chan; Ronald J Bosch; Vicki Stocker; Janine Maenza; Martin Markowitz; Susan Little; Paul E Sax; Ann C Collier; Gary Nabel; Suzanne Saindon; Theresa Flynn; Daniel Kuritzkes; Dan H Barouch Journal: PLoS One Date: 2010-05-10 Impact factor: 3.240
Authors: S Itescu; U Mathur-Wagh; M L Skovron; L J Brancato; M Marmor; A Zeleniuch-Jacquotte; R Winchester Journal: J Acquir Immune Defic Syndr (1988) Date: 1992
Authors: Jintanat Ananworanich; Alexandra Schuetz; Claire Vandergeeten; Irini Sereti; Mark de Souza; Rungsun Rerknimitr; Robin Dewar; Mary Marovich; Frits van Griensven; Rafick Sekaly; Suteeraporn Pinyakorn; Nittaya Phanuphak; Rapee Trichavaroj; Wiriya Rutvisuttinunt; Nitiya Chomchey; Robert Paris; Sheila Peel; Victor Valcour; Frank Maldarelli; Nicolas Chomont; Nelson Michael; Praphan Phanuphak; Jerome H Kim Journal: PLoS One Date: 2012-03-30 Impact factor: 3.240
Authors: James P Williams; Jacob Hurst; Wolfgang Stöhr; Nicola Robinson; Helen Brown; Martin Fisher; Sabine Kinloch; David Cooper; Mauro Schechter; Giuseppe Tambussi; Sarah Fidler; Mary Carrington; Abdel Babiker; Jonathan Weber; Kersten K Koelsch; Anthony D Kelleher; Rodney E Phillips; John Frater Journal: Elife Date: 2014-09-12 Impact factor: 8.140
Authors: Radwa Sharaf; Guinevere Q Lee; Xiaoming Sun; Behzad Etemad; Layla M Aboukhater; Zixin Hu; Zabrina L Brumme; Evgenia Aga; Ronald J Bosch; Ying Wen; Golnaz Namazi; Ce Gao; Edward P Acosta; Rajesh T Gandhi; Jeffrey M Jacobson; Daniel Skiest; David M Margolis; Ronald Mitsuyasu; Paul Volberding; Elizabeth Connick; Daniel R Kuritzkes; Michael M Lederman; Xu G Yu; Mathias Lichterfeld; Jonathan Z Li Journal: J Clin Invest Date: 2018-08-20 Impact factor: 14.808
Authors: Golnaz Namazi; Jesse M Fajnzylber; Evgenia Aga; Ronald J Bosch; Edward P Acosta; Radwa Sharaf; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel Skiest; David Margolis; Michael C Sneller; Susan J Little; Sara Gianella; Davey M Smith; Daniel R Kuritzkes; Roy M Gulick; John W Mellors; Vikram Mehraj; Rajesh T Gandhi; Ronald Mitsuyasu; Robert T Schooley; Keith Henry; Pablo Tebas; Steven G Deeks; Tae-Wook Chun; Ann C Collier; Jean-Pierre Routy; Frederick M Hecht; Bruce D Walker; Jonathan Z Li Journal: J Infect Dis Date: 2018-11-05 Impact factor: 5.226
Authors: Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier Journal: AIDS Res Hum Retroviruses Date: 2018-06-13 Impact factor: 2.205